-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on CARISMA Therapeutics, Maintains $1 Price Target

Benzinga·08/08/2025 12:31:46
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $1 price target.